You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Axsome Therapeutics Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Axsome Therapeutics Company Info
Axsome Therapeutics, Inc
News & Analysis
The next year should be a busy one for this drugmaker.
The good times could keep on rolling for these big winners.
The company seems to be coming into its own.
The biotech's promising Q3 earnings report has investors excited about the future.
Investors traded out of the company following the latest earnings release, but only to a modest degree.
Some guessing is required to figure out what's behind today's big gain.
Both drugmakers have outperformed the market in the past year.
Invest in these stocks if your priority is long-term growth.
AXSM earnings call for the period ending September 30, 2022.
AXSM earnings call for the period ending June 30, 2022.
AXSM earnings call for the period ending March 31, 2022.
AXSM earnings call for the period ending December 31, 2021.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.